CLYYF (Celyad Oncology) Common Stock: $10.79 Mil (As of Dec. 2025)


CLYYF Celyad Oncology SA CLYYF
13 GF Score
Price $0.25
GF Value $0.44
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Common Stock?

Celyad Oncology CLYYF 13 Common Stock is $10.79 Mil as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.44. The stock has 6 warning signs investors should review.

Celyad Oncology's quarterly common stock increased from Dec. 2024 ($8.60 Mil) to Jun. 2025 ($9.48 Mil) and increased from Jun. 2025 ($9.48 Mil) to Dec. 2025 ($10.79 Mil).

Celyad Oncology's annual common stock declined from Dec. 2023 ($35.93 Mil) to Dec. 2024 ($8.60 Mil) but then increased from Dec. 2024 ($8.60 Mil) to Dec. 2025 ($10.79 Mil).

Celyad Oncology Common Stock Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Common Stock Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.80 83.25 35.93 8.60 10.79

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.93 8.84 8.60 9.48 10.79
CLYYF
13GF Score
Celyad Oncology SA CLYYF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $10.79 Mil mean?
Celyad Oncology (CLYYF) has a Common Stock of $10.79 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Celyad Oncology and its competitors.
Is Celyad Oncology's Common Stock too high?
Celyad Oncology's current Common Stock is $10.79 Mil. Overall, Celyad Oncology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Common Stock compare to VRTX and REGN?
Celyad Oncology's Common Stock of $10.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current Common Stock is $10.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current Common Stock of $10.79 Mil. The stock's GF Value™ is $0.44, compared to a current price of $0.25 — trading 43.2% below its estimated fair value. The current Common Stock is $10.79 Mil. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Common Stock is $10.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 43.2% below its estimated GF Value™ of $0.44.

Key valuation signals for CLYYF:

  • Common Stock: $10.79 Mil
  • GF Value™: $0.44 vs. price of $0.25 (43.2% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for CLYYF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.44
GF Value